Phase 2 clinical trial of ATG-010 as targeted therapy for advanced non-small-cell lung cancer initiated in China
Antengene Announces XPOVIO®’s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country
Learn MoreAntengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024
Learn MoreAntengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting
Learn MoreAntengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country
Learn MoreAntengene to Present Results from Three Programs at the 2024 SITC Annual Meeting
Learn MoreAntengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand
Learn MoreChina’s NMPA approves Antengene’s XPOVIO for DLBCL
Learn MoreAntengene Announces XPOVIO® National Health Insurance Service Approval for Reimbursement in South Korea
Learn MoreAntengene announces preclinical study results on PD-L1/4-1BB bispecific antibody ATG-101
Learn MoreAntengene Advances ATG-022 in Phase II CLINCH Study for Solid Tumors in China and Australia
Learn MoreAntengene Enters into Partnership with Hansoh Pharma
Learn MoreAntengene doses first US patient in ATG-017 with nivolumab combination trial
Learn MoreAntengene Announces Results for Full Year 2022 with Updates Highlighting a Revenue Reaching 5.6 Times the Previous Year and Accelerated Global Innovation
Learn MoreAntengene's ATG-022 Phase I CLINCH Trial for Solid Tumor Treatment Receives IND Approval in China
Learn MoreAntengene Announces Participation in the H.C. Wainwright 26th Annual Global Investment Conference
Learn MoreAntengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization
Learn MoreAntengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia
Learn MoreXPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country
Learn MoreAntengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea
Learn MoreAntengene Announces Participation in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
Learn MoreAntengene To Present One Oral and Four Abstracts at ASCO 2024
Learn MoreAntengene Announces One Oral and Three Poster Presentations at ASCO 2024
Learn MoreAntengene Presents Four Preclinical Posters at AACR 2024
Learn MoreAntengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline
Learn MoreAntengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research
Learn MoreAntengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia
Learn MoreAntengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms
Learn MoreAntengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States
Learn MoreAntengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Learn MoreAntengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
Learn MoreAntengene to Host 2023 R&D Day and Discuss Key Data with KOLs
Learn MoreAntengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting
Learn MoreAntengene To Present Results From Five Studies at 2023 SITC Annual Meeting
Learn MoreAntengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
Learn MoreAntengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline
Learn MoreAntengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO® (selinexor) in the Mainland of China
Learn MoreAntengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States
Learn MoreAntengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Learn MoreAntengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Learn MoreAntengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023
Learn MoreAntengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers
Learn MoreAntengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031
Learn MoreAntengene Announces NDA Submission for XPOVIO® in Indonesia
Learn MoreAntengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO
Learn MoreAntengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting
Learn MoreAntengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia
Learn MoreAntengene Announces Results for Full Year 2022 with Updates Highlighting a Revenue Reaching 5.6 Times the Previous Year and Accelerated Global Innovation
Learn MoreAntengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting
Learn MoreAntengene to Host Webcast on Full Year 2022 Financial Results on Tuesday, March 28, 2023
Learn MoreAntengene Announces IND Approval for the Phase I CLINCH Trial of ATG-022 (Claudin 18.2 ADC) for the Treatment of Advanced or Metastatic Solid Tumors in China
Learn MoreAntengene to Present at the 41st Annual J.P. Morgan Healthcare Conference
Learn MoreAntengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)
Learn MoreAntengene Announces NDA Submission for XPOVIO® in Macau,China, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma
Learn MoreAntengene Announces HREC Approval in Australia for the Phase I Trial of ATG-022 (Claudin 18.2 ADC) in Patients with Advanced or Metastatic Solid Tumors
Learn MoreAntengene Appoints Amily Zhang as its Chief Medical Officer
Learn MoreOral Presentation on Antengene's Anti-CD24 Monoclonal Antibody ATG-031 Selected for SITC's Top 100 Abstracts
Learn MoreAntengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer
Learn MoreAntengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting
Learn MorePreliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting
Learn MoreAntengene Announces IND Approval for the Phase I STAMINA-001 Study to Evaluate ATG-037 (CD73 Inhibitor) for the Treatment of Locally Advanced or Metastatic Solid Tumors in China
Learn MoreAntengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors
Learn MoreAntengene to Host Research and Development Day on November 15th and 17th, 2022
Learn MoreAntengene Announces XPOVIO® Regulatory Approval in Taiwan for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
Learn MoreAntengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting
Learn MoreAntengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA
Learn MoreAntengene Unveils Its First Australian Office to Continue Expanding Global Presence
Learn MoreAntengene to Present at Upcoming Industry Conferences
Learn MoreAntengene’s ATG-101 Receives the NMPA’s IND Approval for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma
Learn MoreStudy highlights Antengene's complementary focus on diseases with a higher prevalence in China
Learn MoreAntengene announces XPOVIO approved by Australia for multiple myeloma
Learn MoreSingapore Health Sciences Authority approves Antengene’s Xpovio to treat R/R MM & R/R DLBCL in three indications
Learn MoreAntengene Announces XPOVIO® Included for Reimbursement by the PBS in Australia for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma
Learn MoreAntengene Announces Interim 2022 Financial Results and Provides Corporate Update
Learn MoreAntengene obtaining Korean IND approval for ATG-008, a mTOR Kinase Dual-Targeted Inhibitor
Learn MorePhase 2 clinical trial of ATG-010 as targeted therapy for advanced non-small-cell lung cancer initiated in China
Learn MoreAntengene Appoints Bo Shan as Chief Scientific Officer
Learn MoreAntengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin’s Lymphoma
Learn MoreAntengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
Learn MoreCelgene and Antengene Corporation Announced Long-term Collaboration and Celgene has Become Shareholder of Antengene
Learn MoreAntengene announces China manufacturing plant in Shaoxing, China
Learn MoreAntengene Corporation Attend Qiming Venture Partners CEO Summit
Learn MoreAntengene Corporation Secures $21M in Series A Financing Round Led by Qiming Venture Partners
Learn MoreAntengene Corporation Attend the 20th Annual CSCO Meeting
Learn MoreAntengene Corporation attended Drug Development Case Study Workshop held by CFDA
Learn MoreAntengene Corporation has submitted The Phase 2 Clinical Trial Application of ATG-008 to China, Taiwan and Korea
Learn MoreAntengene Corporation Announces TFDA Approval of IND Application for a Phase II Study of ATG-008, a Next Generation mTOR Inhibitor, in Patients with Late-stage Hepatocellular Carcinoma (HCC)
Learn MoreDr. Yijun Yang and Dr. Bo Shan joined Antengene Corporation
Learn MoreAntengene and Karyopharm Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia
Learn MoreInternational Torch Study (ATG-008-HCC-001) Investigator Meeting held by Antengene
Learn MoreATG-008, China’s first TORC1/2 dual-targeted inhibitor of the new generation, has obtained IND approval
Learn MoreAntengene obtaining Korean IND approval for ATG-008, a mTOR Kinase Dual-Targeted Inhibitor
Learn MoreAntengene Corporation’s Strategic Partner, Karyopharm Therapeutics, Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma
Learn MoreAntengene and WuXi STA announced a strategic cooperation in process R&D and manufacturing
Learn MoreAntengene launches patient enrollment for TORC1/2 dual-targeted inhibitor ATG-008 in Taiwan
Learn MoreAntengene Presents a Series of Reports on TORC1/TORC2 Dual-Targeted Inhibitor ATG-008 at the 21st Annual Meeting of Chinese Society of Clinical Oncology
Learn MoreKaryopharm,Antengene Corporation’s Strategic Partner, Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor (ATG-010)as a Treatment for Patients with Penta-Refractory Multiple Myeloma
Learn MoreAntengene publishes clinical data on ATG-010 (Selinexor) for the treatment of refractory and/or relapsed multiple myeloma and relapsed diffuse large B-cell lymphoma at the Annual Meeting of Chinese Society of Clinical Oncology
Learn MoreAntengene Corporation won the Project Support of “the 13th Five- Year National Major New Drug Development Project”
Learn MoreAntengene Corporation Raises $120 Million in Series B Financing
Learn MoreAntengene Team Standing Out as a Leader in Innovation and Entrepreneurship
Learn MoreATG-010, China’s first Selective Inhibitor of Nuclear Export obtains IND approval for the treatment of multiple myeloma
Learn MoreAntengene Corporation Announces Establishment of U.S. Subsidiary and Collaboration with the Baruch S. Blumberg Institute
Learn MoreStrong alliance for finding a new treatment of liver cancer: Antengene cooperates with Junshi Biosciences to conduct clinical research on the combination therapy of ATG-008 and Toripalimab to treat advanced liver cancer
Learn MoreKaryopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Learn MoreLatest Progress in the treatment of blood cancer with Selinexor, a selective inhibitor of nuclear export
Learn MoreTake the crown! — Antengene was awarded the first prize in the 8th China Innovation& Entrepreneurship Competition
Learn MoreAntengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364
Learn MoreNews Flash! The PAK4/NAMPT Dual Target Oral Inhibitor, ATG-019, Passed the Review of Investigational New Drug (IND) by Taiwan, China
Learn MoreAntengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
Learn MoreFormer Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors
Learn MoreAntengene Presented a Keynote Speech at J.P. Morgan Conference
Learn MoreNews Express! The Clinical Trial of ATG-010 for Peripheral T-cell Lymphoma and NK/T-cell Lymphoma Has Been Approved
Learn MoreNovel oral medication for diffuse large B-cell lymphoma! Another indication of XPOVIO®, a first-in-class nuclear export inhibitor, is expected to achieve accelerated approval
Learn MorePhase 3 Clinical Study of Novel Selective Inhibitor of Nuclear Export Selinexor with New Combination Therapy for Multiple Myeloma Meets Primary Endpoint
Learn MoreClinical trial of Antengene’s ATG-008 in combination with Junshi Biosciences’ Toripalimab for treatment of advanced solid tumors and hepatocellular carcinoma officially initiated
Learn MorePhase 2 clinical trial of ATG-008 as targeted therapy for advanced non-small-cell lung cancer initiated in China
Learn MoreAntengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin’s Lymphoma
Learn MoreAntengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
Learn MoreAntengene Announces First Patient Dosed in China Registration Trial of ATG-010 (selinexor) for Relapsed or Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Learn MoreAntengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets
Learn MoreAntengene Doses First Patient with ATG-008, a mTOR1/2 Dual-targeted Inhibitor, for Advanced Solid Tumors and Hepatocellular Carcinoma of the Clinical Trial with Junshi Biosciences’ Toripalimab
Learn MoreAntengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer
Learn MoreAntengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions
Learn MoreAntengene Appoints Former Celgene ANZ Medical Leader Dirk Hoenemann as Head of Medical Affairs in Asia Pacific Region & Early Clinical Development
Learn MoreAntengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization
Learn MoreAustralian Therapeutic Goods Administration (TGA) Approves the First Phase I Trial of ATG-017 (ERK 1/2 inhibitor) for the Treatment of Patients with Advanced Solid Tumors and Hematological Malignancies
Learn MoreAntengene Announces IND Approval by NMPA to Initiate a Phase II Clinical Trial of ATG-008 for the Treatment of Advanced Solid Tumors with Specific Genetic Alterations
Learn MoreAntengene Announces First Patient Dosed with ATG-010 (selinexor) for Relapsed or Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma
Learn MoreAntengene Announces First Patient Dosing in a Phase I Trial of ATG-017 in Advanced Solid Tumors and Hematological Malignancies in Australia
Learn MoreAntengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines
Learn MoreAntengene’s New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer
Learn MoreAntengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange
Learn MoreApproval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome
Learn MoreAntengene Submits NDAs for XPOVIO® (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL
Learn MoreAntengene Announces Acceptance of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study
Learn MoreAntengene Announces Collaboration with Applied BioMath, LLC for Systems Pharmacology Modeling in Oncology
Learn MoreAntengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM
Learn MoreAntengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM
Learn MoreAntengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
Learn MoreAntengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia
Learn MoreAntengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL
Learn MoreAntengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer
Learn MoreAntengene to Present at the 39th Annual J.P. Morgan Healthcare Conference
Learn MoreRestore the core! Selinexor (ATG-010), a first-in-class drug for multiple myeloma, to be launched in Hainan Free Trade Port
Learn MoreAntengene Announces Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study
Learn MoreAntengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM
Learn MoreAntengene Partners with SAP to Implement an Automated Digital Enterprise Management System
Learn MoreAntengene Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage
Learn MoreAntengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China’s NMPA
Learn MoreAntengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index
Learn MoreAntengene Appoints Minyoung Kim as General Manager of Antengene South Korea
Learn MoreAntengene Included in the Shenzhen-Hong Kong Stock Connect
Learn MoreAntengene Announces Financial Results for Full Year 2020
Learn MoreAntengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021
Learn MoreAntengene Appoints Bo Shan as Chief Scientific Officer
Learn MoreAntengene Appoints Kevin Lynch as Chief Medical Officer
Learn MoreAntengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations
Learn MoreAntengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL
Learn MoreTreatment with Selinexor in Advanced Liposarcoma Demonstrates Clinically Important Reduction in Pain with Improved HRQoL Outcomes
Learn MoreAntengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment
Learn MoreAntengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines
Learn MoreAntengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer
Learn MoreAntengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies
Learn MoreAntengene Announces the IND Approval for Eltanexor in Patients with Advanced Solid Tumors in Mainland China
Learn MoreAntengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial
Learn MoreAntengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)
Learn MoreAntengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development
Learn MoreAntengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome
Learn MoreAntengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021
Learn MoreAntengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021
Learn MoreAntengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021
Learn MoreAntengene’s Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS
Learn MoreAntengene Provides an Update on Its Latest Developments
Learn MoreAntengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)
Learn MoreAntengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies
Learn MoreAntengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma
Learn MoreAntengene and MindRank AI Enter into Collaboration to Advance the Development of Difficult-to-Drug Molecular Targets
Learn MoreAntengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China
Learn MoreAntengene Selected as a Constituent of the FTSE Global Equity Index Series
Learn MoreAntengene Announces Up to HK$100 million Share Repurchase Program
Learn MoreAntengene Announces IND Submitted to U.S. FDA for Its PD-L1/4-1BB Bispecific Antibody ATG-101 in Solid Tumors and Non-Hodgkin Lymphoma
Learn MoreAntengene to Present Data of Its PD-L1/4-1BB Bispecific Antibody ATG-101 and ERK1/2 Inhibitor ATG-017 at SITC 2021
Learn MoreAntengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates
Learn MoreAntengene to Host its First R&D Days on November 16 and November 18, 2021
Learn MoreAntengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting
Learn MoreAntengene Announces IND Approval in China for the Phase I Study of ATG-101 for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma
Learn MoreAntengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes
Learn MoreAntengene Announces XPOVIO® Regulatory Approval in Singapore
Learn MoreAntengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma
Learn MoreAntengene to Present at the 40th Annual J.P. Morgan Healthcare Conference
Learn MoreAntengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037
Learn MoreAntengene’s Pivotal “MARCH” Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine
Learn MoreAntengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting
Learn MoreAntengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Learn MoreAntengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018
Learn MoreAntengene and XtalPi Announce AI-Driven R&D Collaboration
Learn MoreAntengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo (nivolumab) in Advanced Solid Tumors
Learn MoreAntengene Presents Results of Phase 1b TOUCH Trial of Selinexor (ATG-010) for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH)
Learn MoreFirst Patient Dosed in Australia in ATG-101 First-in-Human Trial
Learn MoreAntengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors
Learn MoreAntengene Announces NDA Approval by NMPA for XPOVIO®, China’s First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma
Learn MoreAntengene Included in the MSCI Global Small Cap Indexes – MSCI China Index Constituent Stocks
Learn MoreAntengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021
Learn MoreAntengene to Release Preliminary Results of Phase 1b TOUCH Trial of Selinexor (ATG-010) for the Treatment of Peripheral T-Cell Lymphoma and NKT-Cell Lymphoma at the 2021
Learn MoreAntengene Announces IND Approval in China for a Phase I II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma
Learn MoreAntengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L14-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma
Learn MoreAntengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma
Learn MoreTreating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day
Learn MoreAntengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101
Learn MoreAntengene Announces Research Collaboration with Celularity
Learn More“Research collaboration and introduction of new drugs will continue in South Korea, regarded as an attractive market”
Learn MoreDomestic biopharmaceutical companies will have strong presence globally
Learn MoreAntengene to Participate in Three Upcoming Investor Conferences in May&June
Learn MoreAntengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines
Learn MoreAntengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress
Learn MoreAntengene Announces Commercial Availability of XPOVIO® (Selinexor) Prescribed for the First Time Across Mainland China
Learn MoreAntengene Announces XPOVIO® Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China
Learn MoreAntengene Announces First Patient Dosed in the Phase I II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas
Learn MoreAntengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting
Learn MoreAntengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018
Learn MoreAntengene Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors
Learn MoreAntengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma
Learn More